Covert and Overt Hepatic Encephalopathy: Diagnosis and Management

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 12, 2015, Pages 2048-2061

  Patidar, Kavish R ^a   Bajaj, Jasmohan S ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ammonia; Cirrhosis; Covert Hepatic Encephalopathy; Hepatic Encephalopathy; Lactulose; Overt Hepatic Encephalopathy; Rifaximin

Indexed keywords

ACARBOSE; ALBUMIN; AMMONIA; ANTIBIOTIC AGENT; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZOIC ACID; CARNITINE; DISACCHARIDE; GLUCOSE; GLYCEROL PHENYLBUTYRATE; LACTITOL; LACTULOSE; METRONIDAZOLE; NEOMYCIN; ORNITHINE ASPARTATE; ORNITHINE PHENYLACETATE; OVERT HEPATIC ENCEPHALOPATHY; PAROMOMYCIN; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SORBITOL; VANCOMYCIN; VSL3; ZINC;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALBUMIN DIALYSIS; CHEMOPROPHYLAXIS; COGNITIVE DRUG RESEARCH BATTERY; COMBINATION CHEMOTHERAPY; CONSTIPATION; COVERT HEPATIC ENCEPHALOPATHY; CRITICAL FLICKER FUSION TEST; DEATH; DIARRHEA; DIET THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRIVING ABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; FAMILY; FLATULENCE; HEADACHE; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; INFLAMMATION; INHIBITORY CONTROL TEST; INTESTINE FLORA; LACTOBACILLUS; MEDICATION COMPLIANCE; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NEUROPSYCHOLOGICAL TEST; OTOTOXICITY; OVERT HEPATIC ENCEPHALOPATHY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PSYCHOMETRIC HEPATIC ENCEPHALOPATHY SCORE; QUALITY OF LIFE; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; REVIEW; SENSITIVITY AND SPECIFICITY; SUPPLEMENTATION; DRUG THERAPY; PATHOLOGY; PROCEDURES; SECONDARY PREVENTION;

DRUG THERAPY; EARLY DIAGNOSIS; HEPATIC ENCEPHALOPATHY; HUMANS; MEDICATION ADHERENCE; SECONDARY PREVENTION;

EID: 84944412381     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.06.039     Document Type: Review

References (89)

1. Bustamante J., Rimola A., Ventura P.J., et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999, 30:890-895.
2. Ferenci P., Lockwood A., Mullen K., et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716-721.
3. Vilstrup H., Amodio P., Bajaj J., et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014, 60:715-735.
4. Bajaj J.S., Cordoba J., Mullen K.D., et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011, 33:739-747.
5. Bajaj J.S., Wade J.B., Sanyal A.J. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 2009, 50:2014-2021.
6. Das A., Dhiman R.K., Saraswat V.A., et al. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001, 16:531-535.
7. Ortiz M., Jacas C., Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005, 42(Suppl):S45-S53.
8. Bajaj J.S. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010, 31:537-547.
9. Stepanova M., Mishra A., Venkatesan C., et al. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012, 10:1034-1041.e1.
10. Poordad F.F. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl 1):3-9.
11. Arguedas M.R., DeLawrence T.G., McGuire B.M. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003, 48:1622-1626.
12. Stewart C.A., Malinchoc M., Kim W.R., et al. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl 2007, 13:1366-1371.
13. Wong R.J., Gish R.G., Ahmed A. Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transpl 2014, 20:1454-1461.
14. Conn H.O., Leevy C.M., Vlahcevic Z.R., et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977, 72:573-583.
15. Dhiman R.K., Sawhney M.S., Chawla Y.K., et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000, 45:1549-1552.
16. Groeneweg M., Quero J.C., De Bruijn I., et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998, 28:45-49.
17. Bajaj J.S., Hafeezullah M., Franco J., et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008, 135:1591-1600.e1.
18. Patidar K.R., Thacker L.R., Wade J.B., et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol 2014, 109:1757-1763.
19. Sundaram V., Shaikh O.S. Hepatic encephalopathy: pathophysiology and emerging therapies. Med Clin North Am 2009, 93:819-836. vii.
20. Gerber T., Schomerus H. Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. Drugs 2000, 60:1353-1370.
21. Ott P., Larsen F.S. Blood-brain barrier permeability to ammonia in liver failure: a critical reappraisal. Neurochem Int 2004, 44:185-198.
22. Haussinger D., Kircheis G., Fischer R., et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000, 32:1035-1038.
23. Palomero-Gallagher N., Zilles K. Neurotransmitter receptor alterations in hepatic encephalopathy: a review. Arch Biochem Biophys 2013, 536:109-121.
24. Bajaj J.S. The role of microbiota in hepatic encephalopathy. Gut Microbes 2014, 5:397-403.
25. Shawcross D.L., Davies N.A., Williams R., et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004, 40:247-254.
26. Cordoba J. New assessment of hepatic encephalopathy. J Hepatol 2011, 54:1030-1040.
27. Randolph C., Hilsabeck R., Kato A., et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009, 29:629-635.
28. Goldbecker A., Weissenborn K., Hamidi Shahrezaei G., et al. Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut 2013, 62:1497-1504.
29. Bajaj J.S., Heuman D.M., Sterling R.K., et al. Validation of EncephalApp, Smartphone-Based Stroop Test, for the diagnosis of covert hepatic encephalopathy. Clin Gastroenterol Hepatol 2015, 13:1828-1835.
30. Mardini H., Saxby B.K., Record C.O. Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant. Gastroenterology 2008, 135:1582-1590.
31. Bajaj J.S., Thacker L.R., Heuman D.M., et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology 2013, 58:1122-1132.
32. Amodio P., Pellegrini A., Ubiali E., et al. The EEG assessment of low-grade hepatic encephalopathy: comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis. Clin Neurophysiol 2006, 117:2243-2251.
33. Montagnese S., Amodio P., Morgan M.Y. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. Metab Brain Dis 2004, 19:281-312.
34. Kircheis G., Wettstein M., Timmermann L., et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002, 35:357-366.
35. Sharma P., Sharma B.C., Sarin S.K. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis. Hepatobiliary Pancreat Dis Int 2010, 9:27-32.
36. Nabi E., Thacker L.R., Wade J.B., et al. Diagnosis of covert hepatic encephalopathy without specialized tests. Clin Gastroenterol Hepatol 2014, 12:1384-1389.e2.
37. Ge P.S., Runyon B.A. Serum ammonia level for the evaluation of hepatic encephalopathy. JAMA 2014, 312:643-644.
38. Grover V.P., Dresner M.A., Forton D.M., et al. Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy. World J Gastroenterol 2006, 12:2969-2978.
39. Strauss E., Tramote R., Silva E.P., et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992, 39:542-545.
40. Patidar K.R., Bajaj J.S. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 2013, 28:307-312.
41. Solga S.F. Probiotics can treat hepatic encephalopathy. Med Hypotheses 2003, 61:307-313.
42. Horsmans Y., Solbreux P.M., Daenens C., et al. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997, 11:165-170.
43. Watanabe A., Sakai T., Sato S., et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997, 26:1410-1414.
44. Prasad S., Dhiman R.K., Duseja A., et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45:549-559.
45. Sharma P., Sharma B.C., Puri V., et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008, 20:506-511.
46. Luo M., Li L., Lu C.Z., et al. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2011, 23:1250-1257.
47. Bajaj J.S., Heuman D.M., Wade J.B., et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011, 140:478-487.e1.
48. Sidhu S.S., Goyal O., Mishra B.P., et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011, 106:307-316.
49. Bajaj J.S., Pinkerton S.D., Sanyal A.J., et al. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012, 55:1164-1171.
50. Shukla S., Shukla A., Mehboob S., et al. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 2011, 33:662-671.
51. Lunia M.K., Sharma B.C., Sharma P., et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 2014, 12:1003-1008.e1.
52. Pratap Mouli V., Benjamin J., Bhushan Singh M., et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatol Res 2015, 45:880-889.
53. Bajaj J.S., Heuman D.M., Hylemon P.B., et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014, 39:1113-1125.
54. Simmons F., Goldstein H., Boyle J.D. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 1970, 59:827-832.
55. Rodgers J.B., Kiley J.E., Balint J.A. Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol. Am J Gastroenterol 1973, 60:459-465.
56. Uribe M., Campollo O., Vargas F., et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987, 7:639-643.
57. Elkington S.G., Floch M.H., Conn H.O. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N Engl J Med 1969, 281:408-412.
58. Als-Nielsen B., Gluud L.L., Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004, 2:CD003044.
59. Festi D., Mazzella G., Orsini M., et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res Clin Exp 1993, 54:598-609.
60. Bucci L., Palmieri G.C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993, 13:109-118.
61. Massa P., Vallerino E., Dodero M. Treatment of hepatic encephalopathy with rifaximin: double-blind, double-dummy study versus lactulose. Eur J Clin Res 1993, 4:7-18.
62. Fera G., Agostinacchio F., Nigro M., et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993, 4:57-66.
63. Mas A., Rodes J., Sunyer L., et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003, 38:51-58.
64. Leevy C.B., Phillips J.A. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007, 52:737-741.
65. Paik Y.H., Lee K.S., Han K.H., et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005, 46:399-407.
66. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071-1081.
67. Sharma B.C., Sharma P., Lunia M.K., et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013, 108:1458-1463.
68. Bajaj J.S., Riggio O. Drug therapy: rifaximin. Hepatology 2010, 52:1484-1488.
69. McGee R.G., Bakens A., Wiley K., et al. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011, 11:CD008716.
70. Sharma B.C., Sharma P., Agrawal A., et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009, 137:885-891. 891.e1.
71. Bajaj J.S., Sanyal A.J., Bell D., et al. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010, 31:1012-1017.
72. Mullen K.D., Sanyal A.J., Bass N.M., et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014, 12:1390-1397.e2.
73. Bajaj J.S., Barrett A.C., Bortey E., et al. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther 2015, 41:39-45.
74. Kimer N., Krag A., Moller S., et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014, 40:123-132.
75. Agrawal A., Sharma B.C., Sharma P., et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012, 107:1043-1050.
76. Dhiman R.K., Rana B., Agrawal S., et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014, 147:1327-1337.e3.
77. Stauch S., Kircheis G., Adler G., et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998, 28:856-864.
78. Kircheis G., Nilius R., Held C., et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997, 25:1351-1360.
79. Mittal V.V., Sharma B.C., Sharma P., et al. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2011, 23:725-732.
80. Poo J.L., Gongora J., Sanchez-Avila F., et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 2006, 5:281-288.
81. Sharma K., Pant S., Misra S., et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol 2014, 20:225-232.
82. Alvares-da-Silva M.R., de Araujo A., Vicenzi J.R., et al. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled trial. Hepatol Res 2014, 44:956-963.
83. Jalan R., Wright G., Davies N.A., et al. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007, 69:1064-1069.
84. Ventura-Cots M., Arranz J.A., Simon-Talero M., et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. J Clin Gastroenterol 2013, 47:881-887.
85. Chavez-Tapia N.C., Cesar-Arce A., Barrientos-Gutierrez T., et al. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J 2013, 12:74.
86. Simon-Talero M., Garcia-Martinez R., Torrens M., et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol 2013, 59:1184-1192.
87. Sen S., Davies N.A., Mookerjee R.P., et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004, 10:1109-1119.
88. Hassanein T.I., Tofteng F., Brown R.S., et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007, 46:1853-1862.
89. Amodio P., Bemeur C., Butterworth R., et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013, 58:325-336.